28 November 2011 Business
Industry news, December 2011
US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer. Specifically, regorafenib is to be used when cancer has progressed after treatment and spread to other parts of the body.
Regorafenib was licensed to Bayer in 2011 by US drug maker Onyx, which has already joined up with Bayer on another cancer drug, sorafenib, sold as Nexavar tablets. Regorafenib is a multi-kinase inhibitor that blocks several enzymes involved in cancer growth.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer in the US and the third leading cause of cancer death.
20 March 2012 News and Analysis
For the first time India has invoked a 'compulsory licence' clause to cut the cost of a patented anti-cancer drug
17 May 2013 Research
Barium carbonate crystals have been coaxed to form nano-flowers by controlling their chemical environment
31 January 2013 Business
Dicyandiamide poses no food risk but fertiliser companies have suspended sales